DaVita (DVA) to Release Earnings on Tuesday

DaVita (NYSE:DVA) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $2.76 per share for the quarter. DaVita has set its FY24 guidance at $9.25-10.05 EPS and its FY 2024 guidance at 9.250-10.050 EPS.Parties interested in registering for the company’s conference call can do so using this link.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same quarter last year, the firm earned $2.08 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect DaVita to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

DaVita Trading Down 0.3 %

Shares of DVA stock opened at $161.45 on Tuesday. The company has a market cap of $14.16 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. DaVita has a 1 year low of $75.47 and a 1 year high of $168.50. The stock’s 50 day simple moving average is $156.74 and its two-hundred day simple moving average is $144.69. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

Insider Activity

In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 173,482 shares of company stock valued at $27,387,069. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DVA shares. TD Cowen boosted their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $159.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.